Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)

Trial Profile

Ubenimex in Adult Patients With Lymphedema of The Lower Limb: a Phase 2, RAndomized, Double-blind, Placebo-controlled Study of Efficacy, Safety, and Pharmacokinetics (ULTRA)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Feb 2018

At a glance

  • Drugs Ubenimex (Primary)
  • Indications Lymphoedema
  • Focus Therapeutic Use
  • Acronyms ULTRA
  • Sponsors Eiger BioPharmaceuticals
  • Most Recent Events

    • 31 Jan 2018 Planned End Date changed from 1 Jun 2018 to 1 Sep 2018.
    • 31 Jan 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Sep 2018.
    • 04 Jan 2018 According to an Eiger BioPharmaceuticals media release, enrollment in this trial has been completed and results are expected in second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top